NCT04951050进行中（未招募）不适用
A Prospective, Multicenter, Single-arm Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in Patients With Coronary Artery Stenosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- In-stent late loss
研究概览
简要总结
The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the rapamycin target eluting stent in the treatment of subjects with ischemic heart disease (asymptomatic myocardial ischemia , table or unstable angina), with target lesion(s) in coronary arteries with visually estimated reference vessel diameter ≥2.25mm and ≤4.0 mm.
详细描述
200 participants with coronary artery stenosis will enrolled in the investigation to receive PCI surgery treatment with rapamycin target eluting stent implantation. All the participants will get clinical follow-up after PCI surgery within 30 days, 6 months, 9 months, 12 months and 2-5 years, and they will be conducted coronary angiogram at 9th month after PCI to get the data of in-stent late loss which was the main endpoint of the investigation. The secondary endpoints including device sucess, operation success, clinical sucess, Doce, PoCE, TLR, TVR, MI incident rate, death, stent thrombosis as defined by ARC, stent retraction, MLD, DS and ARB. The data derived from the investigation will be performed statistic analysis to evaluate whether the clinical outcome meet the PG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Patient with an indication for percutaneous coronary intervention (PCI) including silent ischemia (in absence of symptoms a positive functional study or a reversible change in the ECG consistent with ischemia), angina (stable or unstable).
- •Subject acceptable candidate for coronary artery bypass surgery (CABG).
- •Patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule.
- •Angiographic Inclusion Criteria:
- •Treatment up to two target lesions with a maximum of two lesions per epicardial vessel. If there are two target lesions within the same epicardial vessel, the two target lesions must be at least 10mm apart per visual estimation.
- •Target lesion(s) must be located in a native coronary artery with a visually estimated diameter stenosis ≥70%, TIMI 1, lesions length ≤36mm. Target vessel must be visually estimated diameter of ≥2.25mm to ≤4.0mm.
- •Target lesion must be adequately covered with a single stent.
- •Up to two target lesion needed treatment in one target vessel.
- •One non-target lesion is allowed prior to enrollment if successful. It should be located at the distal end of the target lesion, and be at lease 10mm apart, when both are in the same epicardial vessel.
排除标准
- •General Exclusion Criteria:
- •Acute myocardial infarction with 1 week or enzyme levels (Creatinkinase or Troponin) demonstrating that either or both enzyme levels have not returned to normal limits at the time of the procedure.
- •Target vessel (including branches) PCI within 12 months of the baseline procedure.
- •Known congestive heart failure (NYHA III) or left ventricular ejection fraction (LVEF) <30%
- •Patient has current unstable arrhythmias.
- •Patient has a history of any coronary arteries brachytherapy.
- •Planned surgery within 6 months after index procedure.
- •Platelet count <100,000 cells/mm3 or >700,000 cells/mm3, white blood cell (WBC) count <3,000 cells/mm
- •Impaired renal function (serum creatinine >2.0mg/dl) or patient on dialysis.
- •Cerebrovascular accident or transient ischemic attack within the past 6 months, or any permanent neurologic defect attribute to cerebral vascular accident (CVA).
- •Patient has a history of bleeding diathesis, contraindication to dual antiplatelet therapy (DAPT).
- •Known allergy to protocol-required concomitant medications such as aspirin, or clopidogrel, or heparin and the study stent components such as cobalt, nickel, chromium, rapamycin or similar drugs.
- •Patient is participating in or plans to participate in any other investigational drug or device clinical trial that has not reached its primary endpoint.
- •Other serious medical illness with life expectancy less than 1 year (e.g. cancer, congestive heart failure).
- •Patient has immunosuppressive or autoimmune disease, and is receiving or scheduled to immunosuppressive therapy.
- •Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test with on week before treatment.)
- •Women who intend to become pregnant with 12 months after the baseline procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the baseline procedure).
- •Patient has received an organ transplant or is on a waiting list for an organ transplant.
- •Patient is receiving or scheduled to receive chemotherapy or radiotherapy with 30 days before or any time after the baseline procedure.
- •Patient may not be obedient to the clinical investigation plan through the judgment by investigators.
- •Angiographic Inclusion Criteria:
- •Left main artery coronary disease.
- •Three-vessel coronary artery disease.
- •Target lesion is located in or supplied by an arterial or venous bypass graft.
- •In-stent restenosis lesions.
- •Patient has additional lesion(s) for which an intervention with 1 year after the index procedure would be required.
结局指标
主要结局
In-stent late loss
时间窗: 9 months
In-stent late loss at 9 months post-procedure as measured by quantitative coronary angiography (QCA)
次要结局
- Any myocardial ischemia (MI)(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- Device success(0 day)
- Procedure success(During the hospital stay to a maximum of the first seven days post index procedure)
- Patient oriented composite endpoint (PoCE)(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- In-stent and in-segment %diameter stenosis (%DS)(9 months)
- Target Lesion Failure(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- Any revascularization(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- Ischemia-driven TLR(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- Late lumen loss in segment(9 months)
- In-stent and in-segment binary restenosis rate(9 months)
- Target lesion success(0 day)
- target vessel revascularization (TVR)(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- In-stent and in-segment minimum lumen diameter(9 months)
- Probable and definite stent thrombosis defined by Academic Research Consortium (ARC)(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
- TLR(30days, 6 months, 9months, 12 months and yearly thereafter until 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialDiffuse Large B-Cell LymphomaNCT01534949Celltrion1
已完成
1 期
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerGastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionCarcinoma, Transitional CellBiliary Tract CancerNon-small Cell Lung CancerNCT02443324Eli Lilly and Company175
进行中（未招募）
3 期
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDNMOSDNeuromyelitis Optica Spectrum DisordersNCT06724809Alexion Pharmaceuticals, Inc.21
招募中
不适用
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula StenosisArteriovenous Fistula StenosisNCT06422845DK Medical Technology (Suzhou) Co., Ltd.328
已完成
1 期
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT04914286Genfleet Therapeutics (Shanghai) Inc.148